These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 554432)

  • 1. [Cardiovascular effect of a new antiarrhythmic drug--changrolin (author's transl)].
    Chen WZ; Dong YL; Ding GS
    Yao Xue Xue Bao; 1979 Dec; 14(12):710-4. PubMed ID: 554432
    [No Abstract]   [Full Text] [Related]  

  • 2. [A study of cardiovascular and antiarrhythmic effects of alizapride (author's transl)].
    Cheymol G; Mouillé P
    Sem Hop; 1982 Feb; 58(6):333-8. PubMed ID: 6280298
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cardiovascular effects and antiarrhythmic action of a new beta adrenergic blocker, LB-46].
    Yoshida T; Takano M; Tamura A; Kubota H; Suzuki N
    Masui; 1970 May; 19(5):515-22. PubMed ID: 4393894
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of antiarrhythmic drug changrolin on myocardial contractility in anesthetized dogs (author's transl)].
    Shen YT; Wu PM; Wan FT; Chen WZ; Dong YL
    Zhongguo Yao Li Xue Bao; 1981 Mar; 2(1):23-6. PubMed ID: 6461194
    [No Abstract]   [Full Text] [Related]  

  • 5. [Dihydralazin versus prazosin. The hemodynamic effect of the modul substances (author's transl)].
    Komarek J; Cartheuser CF
    Z Kardiol; 1977 Dec; 66(12):706-11. PubMed ID: 602353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on drugs for coronary diseases. II. Synthesis of compounds related to changrolin as potential antiarrhythmic drugs (author's transl)].
    Sun CJ; Zhang XY; Yang XZ; Wang PP; Shen J; Shu Y; Ji RY
    Yao Xue Xue Bao; 1981 Aug; 16(8):564-70. PubMed ID: 7324955
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effects of infusion rate of Changrolin on drug concentration in blood and ECG (author's transl)].
    Qu ZX; Cao CY; Zhuang YH
    Yao Xue Xue Bao; 1980 Aug; 15(8):449-55. PubMed ID: 7211388
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of antiarrhythmic and other cardiac activities in some newly synthesized quinazolone compounds.
    Singh N; Kulshrestha VK; Shamsi MA; Kohli RP; Bhargava KP
    Arch Int Pharmacodyn Ther; 1972; 198(1):94-106. PubMed ID: 5053244
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular effects of equi-antiarrhythmic doses of alprenolol (a beta-adrenergic receptor antagonist) diphenylhydantoin and procainamide.
    Proctor JD; Allen FJ; Wasserman AJ
    Arch Int Pharmacodyn Ther; 1971 Apr; 190(2):354-67. PubMed ID: 4396926
    [No Abstract]   [Full Text] [Related]  

  • 10. [Comparative animal experimental studies of the effectivity of various blood vessel and myocardium ACTIVE SUBSTANCES IN AN ACUTE TRIAL].
    Urbaszek W; Kalkowski H; Günther K; Splith G; Trenckmann H
    Z Gesamte Inn Med; 1969 Feb; 24(4):102-8. PubMed ID: 4978753
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effects of non-depolarizing neuromuscular blocking agents on the cardiac contractility and cardiovascular system (author's transl)].
    Matsukawa S
    Masui; 1980 Jul; 29(7):648-56. PubMed ID: 7411843
    [No Abstract]   [Full Text] [Related]  

  • 12. N-n-propyl-ajmaline-bitartrate (NPAB), a new antiarrhythmic drug. Comparative studies on the antifibrillatory and hemodynamic effects in the anaesthetised cat.
    Diederich KW; Boyksen D
    Arzneimittelforschung; 1973 Sep; 23(9):1302-5. PubMed ID: 4801225
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hemodynamic properties of a new derivative of theophylline: bamifylline].
    Moret PR; Fournet PC; Boufas D
    Schweiz Med Wochenschr; 1970 Mar; 100(10):462-7. PubMed ID: 5423732
    [No Abstract]   [Full Text] [Related]  

  • 14. Protamine sulfate administration and the cardiovascular system.
    Gourin A; Streisand RL; Greineder JK; Stuckey JH
    J Thorac Cardiovasc Surg; 1971 Aug; 62(2):193-204. PubMed ID: 5560501
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic analysis of changrolin in dogs with arrhythmia.
    Liu CX; Gu YB; Feng JL; Wei GL; Xiao SH; Sun JL
    Yao Xue Xue Bao; 1996; 31(9):666-70. PubMed ID: 9863232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new antiarrhythmic drug.
    Rydén L
    Acta Med Scand Suppl; 1974; 569():1-40. PubMed ID: 4533723
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antiarrhythmic effect of 4-(3',5'-bis ((n-pyrrolidinyl) methyl)-4'-hydroxyanilino) quinazoline (changrolin) on aconitine-induced arrhythmia in rats (author's transl)].
    Wang ZM; Zhang YF; Ding GS
    Yao Xue Xue Bao; 1979 Jul; 14(7):408-11. PubMed ID: 532636
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of Bepridil on respiratory and cardiovascular function: a placebo-controlled study.
    Forche G; Kopera H; Marsoner HJ
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):234-40. PubMed ID: 6602783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of cardiovascular effect of neuroleptanesthesia (Part I)--cardiovascular effect of pentazocine (author's transl)].
    Sone T
    Masui; 1980 Mar; 29(3):225-31. PubMed ID: 7373840
    [No Abstract]   [Full Text] [Related]  

  • 20. [Changes induced by various concentrations of halothane in the cardiovascular system. (Experimental study)].
    Tonelli F; Fantera A
    Acta Anaesthesiol; 1970; 31():Suppl:1-15. PubMed ID: 5538009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.